Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06WPM
|
||||
| Former ID |
DIB004329
|
||||
| Drug Name |
Coprexa
|
||||
| Synonyms |
Tetrathiomolybdate
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Neurological disease [ICD9: 338, 338.2, 410, 782.3,780; ICD10:I21, I22, R52, R52.1-R52.2, R60.9, G89] | Phase 3 | [1] | ||
| Company |
Pipex Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
H2MoS4-2
|
||||
| Canonical SMILES |
[SH-].[SH-].S=[Mo]=S
|
||||
| InChI |
1S/Mo.2H2S.2S/h;2*1H2;;/p-2
|
||||
| InChIKey |
VVRHUOPINLMZBL-UHFFFAOYSA-L
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Superoxide dismutase [Cu-Zn] | Target Info | Inhibitor | [1] | |
| BioCyc Pathway | Reactive oxygen species degradation | ||||
| KEGG Pathway | Peroxisome | ||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| Huntington's disease | |||||
| Prion diseases | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| Pathway Interaction Database | Validated nuclear estrogen receptor alpha network | ||||
| FOXA1 transcription factor network | |||||
| PathWhiz Pathway | Degradation of Superoxides | ||||
| Reactome | Platelet degranulation | ||||
| Detoxification of Reactive Oxygen Species | |||||
| WikiPathways | Oxidative Stress | ||||
| Copper homeostasis | |||||
| Detoxification of Reactive Oxygen Species | |||||
| Nifedipine Activity | |||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| Dopamine metabolism | |||||
| AGE/RAGE pathway | |||||
| Folate Metabolism | |||||
| Vitamin B12 Metabolism | |||||
| Selenium Micronutrient Network | |||||
| References | |||||
| REF 1 | Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006 Aug 15;12(16):4974-82. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.